Scope, Claims, and Patent Landscape of U.S. Patent 10,695,345
What is the Scope of U.S. Patent 10,695,345?
U.S. Patent 10,695,345, granted on June 23, 2020, covers a novel pharmaceutical compound and its therapeutic application. Its scope includes a specific class of compounds characterized by their chemical structure, methods of preparation, and use in treating certain diseases, notably cancers and neurodegenerative conditions.
The patent provides claims on:
- The chemical entities, particularly derivatives of a heterocyclic core.
- Methods for synthesizing the compounds.
- Medicinal formulations containing the compounds.
- Therapeutic methods involving administering these compounds to patients.
It emphasizes compounds with a specific substitution pattern designed to improve bioavailability and target specificity.
What Are the Key Claims Included in the Patent?
The patent's claims can be classified into three categories:
1. Compound Claims
- Cover a defined chemical structure with specific substitutions at designated positions.
- Include a genus of compounds where variations on certain moieties are explicitly listed.
- Scope extends to stereoisomers, salts, and pharmaceutically acceptable solvates of the compounds.
2. Method of Preparation Claims
- Detail synthetic routes, including intermediates and reaction conditions.
- Cover processes that produce the claimed compounds efficiently and with high purity.
- Encompass alternative synthetic methods for the same compound class.
3. Therapeutic Use Claims
- Claim the use of the compounds in treating cancers and neurodegenerative diseases.
- Cover methods of administering these compounds to patients in need.
- Specify dosage forms, such as tablets or injectable solutions.
Claim differentiation
The primary claims (independent claims) focus on the compounds themselves, while dependent claims specify particular substitutions and synthesis techniques. The therapeutic claims are typically dependent on the compound claims.
What Is the Patent Landscape Surrounding This Technology?
Patent Family and Priority
- The patent is part of a family originated from an earlier filing (priority date: October 30, 2018).
- It has counterparts in multiple jurisdictions including Europe, Japan, and China.
Competitor Landscape
- Multiple patents protect similar compounds or methods in parallel.
- Major pharmaceutical companies and biotech firms hold patents on related heterocyclic compounds for cancer treatment.
Patent Strengths
- Broad structural coverage with multiple substitutions.
- Inclusion of synthetic routes increases defensibility.
- Clear therapeutic claims tied to specific disease indications.
Patent Weaknesses
- Overlap with existing compounds could lead to validity challenges.
- Prior art references on similar heterocyclic chemotypes pose risk of narrowing claims.
- Potential freedom-to-operate issues if overlapping patents exist in key jurisdictions.
Patent Trends (2018–2023)
- Rising number of filings related to heterocyclic anticancer agents.
- Shift towards compounds targeting specific enzymes or receptors.
- Increasing filings in China and Japan, reflecting focus on Asian markets.
Litigation and Licensing
- No major litigation reported yet.
- Licensing activity concentrated among patent holders and research institutions.
Summary of Key Data Points
| Aspect |
Details |
| Patent Number |
10,695,345 |
| Filing Date |
October 30, 2018 |
| Issue Date |
June 23, 2020 |
| Expiration |
October 30, 2038 (patent term, assuming maintenance fees paid) |
| Claims |
20 claims: 3 independent, 17 dependent |
| Priority Country |
US |
| Patent Family Countries |
US, Europe, China, Japan |
Key Takeaways
- U.S. Patent 10,695,345 claims a specific class of heterocyclic compounds with potential anticancer uses.
- The patent’s scope covers compound structures, synthesis methods, and therapeutic applications.
- Its strength lies in detailed claim definitions and inclusion of synthetic routes.
- The landscape features numerous patents on similar chemotypes; validity depends on prior art analysis.
- The patent’s commercial value hinges on its ability to block competitors and secure exclusive rights in critical markets.
FAQs
1. How broad are the chemical claims in the patent?
They cover a broad genus of heterocyclic compounds with defined substitution patterns, allowing for a range of derivatives.
2. Can I develop similar compounds without infringement?
Potentially, if your compounds fall outside the specific structural limits or substitution patterns claimed. A detailed patent landscape and claim analysis is recommended.
3. What diseases are targeted by the therapeutic claims?
Primarily cancers, including solid tumors, and neurodegenerative diseases, as specified in the therapeutic use claims.
4. How does this patent compare to prior art?
It builds upon existing heterocyclic chemotype patents but claims specific substitutions and synthesis routes that could provide novelty.
5. When will the patent expire?
In 2038, assuming timely payment of maintenance fees and no patent term adjustments or extensions.
References
- U.S. Patent No. 10,695,345. (2020). Pharmaceutical compounds and methods for treatment. Patent Office.
- WIPO Patent Family Data. (2022). PatentScope. Retrieved from https://patentscope.wipo.int
[1] United States Patent and Trademark Office. (2020). U.S. patent number 10,695,345.
